Abliva to participate in World Mitochondrial Disease Week 2022

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will participate in this year’s World Mitochondrial Disease Week through videos that will be released on Abliva’s website daily during the week, 18 – 24 September.

The videos will be focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases. Over the week, we will highlight the important role patients have played in informing our strategy, discuss Abliva’s efforts to treat mitochondrial disease patients with our two novel, first-in class compounds, KL1333 and NV354, and hear from a patient, Daniela Gallo, about her struggles with the disease.

Starting 18 September, Abliva’s videos will be posted daily on https://abliva.com/poster/presentationer/world-mitochondrial-disease-week-2022/ as well as on the company’s YouTube channel and LinkedIn page.

World Mitochondrial Disease Week is an initiative of International Mito Patients (IMP). The purpose of the World Mitochondrial Disease Week is to raise awareness of mitochondrial disease (mito) on a global scale through educational, fundraising, and advocacy activities.
https://mitochondrialdiseaseweek.org.

Upcoming event
Abliva’s CEO Ellen Donnelly will present the company at Aktiespararna’s Aktiedagen Lund, at Elite Hotel Ideon, on September 26, 2022, at 4 p.m. The event will be available live and on demand at http://www.aktiespararna.se/tv/live and http://www.youtube.com/Aktiespararna.

About primary mitochondrial diseases

Primary mitochondrial diseases are metabolic diseases that affect the cells’ ability to convert energy. The diseases can manifest very differently depending on the organs impacted and the number of dysfunctional mitochondria in that organ. Historically viewed as clinical syndromes, our knowledge about the various mutations underlying mitochondrial diseases has increased, improving our ability to identify and treat these patients. It is estimated that 125 persons per million have a primary mitochondrial disease. The diseases often present in early childhood and lead to severe symptoms such as mental retardation, fatigue, myopathy, heart failure and rhythm disturbances, diabetes, movement disorders, stroke-like episodes, and epileptic seizures.

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Abliva to participate in World Mitochondrial Disease Week 2022